Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension
Shalini M Krishnan, Yeong H Ling, Brooke M Huuskes, Dorota M Ferens, Narbada Saini, Christopher T Chan, Henry Diep, Michelle M Kett, Chrishan S Samuel, Barbara K Kemp-Harper, Avril AB Robertson, Matthew A Cooper, Karlheinz Peter, Eicke Latz, Ashley S Mansell, Christopher G Sobey, Grant R Drummond, Antony Vinh
Cardiovascular Research | OXFORD UNIV PRESS | Published : 2019
Awarded by National Health and Medical Research Council of Australia
Awarded by European Research Council InflammAct
This work was supported by the National Health and Medical Research Council of Australia (APP1143674 to G.R.D., A.M., C.S., and A.V.; APP1062721 to G.R.D., C.S., A.M. and E.L.; APP1006017 to G.R.D.; APP1079467 to C.G.S.; APP1079492 to K.P.; and APP1041766 to C.S.S.), the European Research Council InflammAct (616777 to E.L.) and the TRR57 grant by the Deutsche Forschungsgemeinschaft (to E.L.).